share_log

More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases

More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases

裸蓋菇鹼的更多專利申請:了解 NOVA 對神經系統疾病的迷幻治療
Benzinga Real-time News ·  2022/06/16 13:40

The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB:NMLSF) is filing new provisional patent applications to the U.S. Patent and Trademark Office (USPTO) in order to protect potential conclusions from its psilocybin preclinical studies as well as its proprietary therapy with psilocybin and psilocybin-based tryptamine derivatives for neuroinflammatory disorders (NID).

加拿大生物技術公司 新明思生命科學股份有限公司 (OTCQB: NMLSF) 正在提交新的臨時專利申請 美國專利及商標局 為了保護潛在的結論從裸蓋菇鹼臨床前研究,以及其專有的治療與裸蓋菇鹼和基於裸蓋菇素的色胺衍生物 神經炎症性疾病(NID)

NOVA's therapeutic paradigm includes diagnosis, monitoring and treating neuroinflammatory diseases and conditions with psychoactive tryptamine derivatives. Their research program aims to respond to the need for an accurate and effective diagnosis & treatment of NID by generating clinical biomarker data for aberrant gene expression and cellular communication in neurological disease or injury, and by providing insights into possible interventions and disease monitoring.

NOVA 的治療範式包括使用精神活性色胺衍生物診斷,監測和治療神經炎症性疾病和病症。他們的研究計劃旨在通過生成來響應對準確有效診斷和治療 NID 的需求 用於神經系統疾病或損傷中異常基因表達和細胞通信的臨床生物標誌物數據, 並通過提供有關可能的干預措施和疾病監測的見解.

Dr. Marvin S. Hausman MD, chairman of NOVA's Scientific Advisory Board, affirmed that the current patent application filing represents a "major milestone" in their psilocybin research program.

奧斯曼博士醫學博士,NOVA 科學顧問委員會主席, 肯定目前的專利申請文件代表了一個「重要里程碑」在他們的裸蓋菇鹼研究計劃.

"The company is now in a position to reveal the breakthrough preclinical psilocybin results uncovered in its treatment of fragile X syndrome (FXS)," Hausman said. "Oral repetitive doses of microdose psilocybin showed a more robust improvement in memory than the same doses given by injection. Metabolic changes of psilocybin within the small intestine and perhaps the microbiome may represent a new paradigm in the application of psilocybin to the treatment of autism spectrum disorder (ASD)." 

奧斯曼說:「該公司目前正在揭示其治療脆性 X 綜合徵(FXS)中發現的突破性臨床前裸蓋菇鹼結果。「口服重複劑量的微劑量裸蓋菇鹼表現出比注射給出的相同劑量更強大的改善記憶.小腸內裸蓋菇鹼的代謝變化,也許微生物組可能代表裸蓋菇鹼對治療自閉症譜系障礙(ASD)的應用的新範式。」

As stated by the company, the psilocybin formulation was evaluated in two distinct rat models of autism in the laboratory of Dr. Viviana Trezza in Italy, and demonstrated psilocybin proof of efficacy and safety. In February, NOVA announced it had successfully completed its preclinical study which confirmed oral microdose psilocybin as a potential treatment option for ASD and FXS

正如該公司所述,裸蓋菇鹼配方在自閉症的實驗室中進行了兩種不同的大鼠模型進行了評估 维维亚娜·特雷扎博士 在意大利, 並證明裸蓋菇鹼的有效性和安全性證明. 二月份NOVA 宣布已成功完成其臨床前研究,證實口服微劑量裸蓋菇鹼為潛力 自閉症和 FXS 的治療選擇

The February research found that a repeated low dose of the proprietary psilocybin drug NM-1001 significantly modulated behavioral and cognitive defects such as recognition memory in a genetic model of FXS. The conclusive data from the study will be presented at the 18th NFXF International Fragile X Conference later this year. 

2 月份的研究發現,重複低劑量的專有裸蓋菇鹼藥物 納米 -1001 顯著調節的行為和認知缺陷,例如 FXS 遺傳模型中的識別記憶。該研究的確鑿性數據將於今年晚些時候在第 18 屆 NFXF 國際脆弱 X 會議上發表。

The fact is that NOVA keeps strengthening its intellectual property by presenting provisional patent applications to protect data from a number of trials recently.

事實是,NOVA 通過提出臨時專利申請來保護數據免受多次試驗的侵害,不斷增強其知識產權。

Previously, the company had filed provisional patent applications for the following: a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin, and a diagnostic/therapeutic combination of mRNA molecules that encodes proteins involved in the development of the neurodegenerative diseases FXS and ASD.

此前,該公司已針對以下項目提出了臨時專利申請: 專利製造流程 用於生產裸蓋菇鹼和色胺類似物,巴歐青素和綠黴素,以及 mRNA 分子的診斷與治療組合 編碼參與神經退行性疾病 FXS 和 ASD 發展的蛋白質。

The conclusive data from NOVA's most recent study will be presented at the 18th NFXF International Fragile X Conference later this year. 

NOVA 最近研究的確鑿性數據將在今年晚些時候的第 18 屆 NFXF 國際脆弱 X 會議上發表。

Photo Courtesy of Pexels.

照片由 Pexels 提供。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論